BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 27822706)

  • 1. Targeting CXCR4 and FAK reverses doxorubicin resistance and suppresses invasion in non-small cell lung carcinoma.
    Dragoj M; Milosevic Z; Bankovic J; Tanic N; Pesic M; Stankovic T
    Cell Oncol (Dordr); 2017 Feb; 40(1):47-62. PubMed ID: 27822706
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-invasive effects of CXCR4 and FAK inhibitors in non-small cell lung carcinomas with mutually inactivated p53 and PTEN tumor suppressors.
    Dragoj M; Bankovic J; Sereti E; Stojanov SJ; Dimas K; Pesic M; Stankovic T
    Invest New Drugs; 2017 Dec; 35(6):718-732. PubMed ID: 28733702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Focal Adhesion Kinase Inhibitors in Combination with Erlotinib Demonstrate Enhanced Anti-Tumor Activity in Non-Small Cell Lung Cancer.
    Howe GA; Xiao B; Zhao H; Al-Zahrani KN; Hasim MS; Villeneuve J; Sekhon HS; Goss GD; Sabourin LA; Dimitroulakos J; Addison CL
    PLoS One; 2016; 11(3):e0150567. PubMed ID: 26962872
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypoxia can impair doxorubicin resistance of non-small cell lung cancer cells by inhibiting MRP1 and P-gp expression and boosting the chemosensitizing effects of MRP1 and P-gp blockers.
    Chen YL; Yang TY; Chen KC; Wu CL; Hsu SL; Hsueh CM
    Cell Oncol (Dordr); 2016 Oct; 39(5):411-433. PubMed ID: 27306525
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential expression of CXCR4 is associated with the metastatic potential of human non-small cell lung cancer cells.
    Su L; Zhang J; Xu H; Wang Y; Chu Y; Liu R; Xiong S
    Clin Cancer Res; 2005 Dec; 11(23):8273-80. PubMed ID: 16322285
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CXCR4 promotes cisplatin-resistance of non-small cell lung cancer in a CYP1B1-dependent manner.
    Xie S; Tu Z; Xiong J; Kang G; Zhao L; Hu W; Tan H; Tembo KM; Ding Q; Deng X; Huang J; Zhang Q
    Oncol Rep; 2017 Feb; 37(2):921-928. PubMed ID: 27922681
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Visfatin mediates doxorubicin resistance in human non-small-cell lung cancer via Akt-mediated up-regulation of ABCC1.
    Cao Z; Liang N; Yang H; Li S
    Cell Prolif; 2017 Oct; 50(5):. PubMed ID: 28762597
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro and in vivo therapeutic efficacy of CXCR4 antagonist BKT140 against human non-small cell lung cancer.
    Fahham D; Weiss ID; Abraham M; Beider K; Hanna W; Shlomai Z; Eizenberg O; Zamir G; Izhar U; Shapira OM; Peled A; Wald O
    J Thorac Cardiovasc Surg; 2012 Nov; 144(5):1167-1175.e1. PubMed ID: 22925564
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic Potential of Focal Adhesion Kinase Inhibition in Small Cell Lung Cancer.
    Aboubakar Nana F; Lecocq M; Ladjemi MZ; Detry B; Dupasquier S; Feron O; Massion PP; Sibille Y; Pilette C; Ocak S
    Mol Cancer Ther; 2019 Jan; 18(1):17-27. PubMed ID: 30352800
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced antitumor and anti-metastasis efficiency via combined treatment with CXCR4 antagonist and liposomal doxorubicin.
    Mei L; Liu Y; Zhang Q; Gao H; Zhang Z; He Q
    J Control Release; 2014 Dec; 196():324-31. PubMed ID: 25450404
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective targeting of FAK-Pyk2 axis by alpha-naphthoflavone abrogates doxorubicin resistance in breast cancer cells.
    Datta A; Bhasin N; Kim H; Ranjan M; Rider B; Abd Elmageed ZY; Mondal D; Agrawal KC; Abdel-Mageed AB
    Cancer Lett; 2015 Jun; 362(1):25-35. PubMed ID: 25796439
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Resveratrol enhances chemosensitivity of doxorubicin in multidrug-resistant human breast cancer cells via increased cellular influx of doxorubicin.
    Kim TH; Shin YJ; Won AJ; Lee BM; Choi WS; Jung JH; Chung HY; Kim HS
    Biochim Biophys Acta; 2014 Jan; 1840(1):615-25. PubMed ID: 24161697
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Schedule-dependent cytotoxicity of sunitinib and TRAIL in human non-small cell lung cancer cells with or without EGFR and KRAS mutations.
    Bao YX; Zhao XD; Deng HB; Lu CL; Guo Y; Lu X; Deng LL
    Cell Oncol (Dordr); 2016 Aug; 39(4):343-52. PubMed ID: 27016208
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alpha-enolase promotes cell glycolysis, growth, migration, and invasion in non-small cell lung cancer through FAK-mediated PI3K/AKT pathway.
    Fu QF; Liu Y; Fan Y; Hua SN; Qu HY; Dong SW; Li RL; Zhao MY; Zhen Y; Yu XL; Chen YY; Luo RC; Li R; Li LB; Deng XJ; Fang WY; Liu Z; Song X
    J Hematol Oncol; 2015 Mar; 8():22. PubMed ID: 25887760
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reversal of cisplatin resistance in non-small cell lung cancer stem cells by Taxus chinensis var.
    Jiang YQ; Xu XP; Guo QM; Xu XC; Liu QY; An SH; Xu JL; Su F; Tai JB
    Genet Mol Res; 2016 Sep; 15(3):. PubMed ID: 27706681
    [TBL] [Abstract][Full Text] [Related]  

  • 16. miR-199a-5p is involved in doxorubicin resistance of non-small cell lung cancer (NSCLC) cells.
    Jin Y; Wang H; Zhu Y; Feng H; Wang G; Wang S
    Eur J Pharmacol; 2020 Jul; 878():173105. PubMed ID: 32278855
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enterolactone alters FAK-Src signaling and suppresses migration and invasion of lung cancer cell lines.
    Chikara S; Lindsey K; Borowicz P; Christofidou-Solomidou M; Reindl KM
    BMC Complement Altern Med; 2017 Jan; 17(1):30. PubMed ID: 28068967
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of PTPN13 in invasion and metastasis of lung squamous cell carcinoma.
    Han X; Xue L; Zhou L; Gong L; Zhu S; Yao L; Wang S; Lan M; Li Y; Zhang W
    Exp Mol Pathol; 2013 Dec; 95(3):270-5. PubMed ID: 23906871
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acacetin enhances the therapeutic efficacy of doxorubicin in non-small-cell lung carcinoma cells.
    Punia R; Raina K; Agarwal R; Singh RP
    PLoS One; 2017; 12(8):e0182870. PubMed ID: 28859099
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Excision repair cross complementation group 1 is a chemotherapy-tolerating gene in cisplatin-based treatment for non-small cell lung cancer.
    Wang S; Pan H; Liu D; Mao N; Zuo C; Li L; Xie T; Huang D; Huang Y; Pan Q; Yang L; Wu J
    Int J Oncol; 2015 Feb; 46(2):809-17. PubMed ID: 25434755
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.